Jul. 11 at 10:01 AM
$MVMDF
🔥 FDA PCAC MEETING IS THIS WEEK: July 23-24, 2026 — the FDA Pharmacy Compounding Advisory Committee reviews BPC-157, KPV, TB-500, and MOTS-C for 503A compounding eligibility.
$MVMD $MVMDF $20MP has Quicksome™ sublingual formulations of BPC-157, GHK-Cu, KPV, SNAP-8, and retatrutide ALREADY COMPLETED. The stock is up 220% YoY. This is the catalyst week. DYOR. #BPC157 #FDA #Peptides #MVMD